TY  - JOUR
AU  - Pomykala, K. L.
AU  - Hadaschik, B. A.
AU  - Sartor, O.
AU  - Gillessen, S.
AU  - Sweeney, C. J.
AU  - Maughan, T.
AU  - Hofman, M. S.
AU  - Herrmann, Markus
TI  - Next Generation Radiotheranostics Promoting Precision Medicine.
JO  - Annals of oncology
VL  - 34
IS  - 6
SN  - 0923-7534
CY  - Amsterdam [u.a.
PB  - Elsevier
M1  - DKFZ-2023-00541
SP  - 507-519
PY  - 2023
N1  - 2023 Jun;34(6):507-519
AB  - Radiotheranostics is a field of rapid growth with some approved treatments including 131I for thyroid cancer, 223Ra for osseous metastases, 177Lu-Dotatate for neuroendocrine tumors, and 177Lu-PSMA for prostate cancer, and several more under investigation. In this review, we will cover the fundamentals of radiotheranostics, the key clinical studies that have led to current success, future developments with new targets, radionuclides and platforms, challenges with logistics and reimbursement and, lastly, forthcoming considerations regarding dosimetry, identifying the right line of therapy, artificial intelligence and more.
KW  - (177)Lu-Dotatate (Other)
KW  - (177)Lu-PSMA (Other)
KW  - endoradiotherapy (Other)
KW  - positron emission tomography (Other)
KW  - radiotheranostics (Other)
KW  - targeted radioligand therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36924989
DO  - DOI:10.1016/j.annonc.2023.03.001
UR  - https://inrepo02.dkfz.de/record/274335
ER  -